Bristol-Myers Squibb Projects Strong 2026 Earnings Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy BMY?
Source: NASDAQ.COM
- 2026 Earnings Guidance: Bristol-Myers Squibb projects adjusted earnings per share between $6.05 and $6.35 for 2026, exceeding analyst expectations and reflecting the company's confidence in its future profitability.
- Revenue Growth Forecast: The company anticipates total worldwide revenues of approximately $46.0 billion to $47.5 billion in 2026, compared to analysts' average estimate of $44.22 billion, indicating strong competitive positioning and growth potential in the market.
- Analyst Expectations Comparison: While analysts expect a revenue decline of 7.85% for 2026, Bristol-Myers Squibb's optimistic projections suggest positive developments in drug development and market expansion, potentially attracting more investor interest.
- Market Reaction: In pre-market trading on Thursday, BMY shares rose by 1.75% to $58.64, reflecting market optimism regarding the company's financial outlook, which may drive further stock price appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 59.860
Low
37.00
Averages
55.86
High
68.00
Current: 59.860
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Tech Sector Rebound Fails to Offset Weekly Losses
- Nasdaq Rebound: The Nasdaq gained over 2% on Friday, yet still posted a 1.8% decline for the week, indicating ongoing investor concerns about tech stocks and the need to monitor future market trends.
- Dow Hits All-Time High: The Dow surged more than 1,200 points on Friday, closing at 50,115 with a weekly gain of 2.5%, reflecting a shift of funds from growth to value stocks, which may influence future investment strategies.
- Surge in Capital Expenditures: Alphabet announced that its capital expenditures for 2026 could exceed double the previous year, and despite a 0.5% drop in shares on Thursday, market confidence in its AI investments remains strong, signaling expectations for future growth.
- Software Stocks Crushed: Software stocks faced significant declines due to fears of AI encroaching on traditional SaaS companies, leading to pressure on the entire tech sector, prompting investors to remain vigilant about potential risks and opportunities within the industry.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
US Stocks Plunge as Tech Sector Leads Decline
- Tech Sector Decline: Qualcomm's (QCOM) forecast of weaker-than-expected Q2 revenue led to an over 8% drop in its stock, triggering a sell-off across the tech sector, with the Nasdaq 100 index hitting a 2.5-month low, indicating waning investor confidence in technology stocks.
- Weak Labor Market Signals: Challenger's report revealed a staggering 117.8% year-over-year increase in job cuts for January, totaling 108,435, the highest for January since 2009, while initial jobless claims rose by 22,000 to 231,000, highlighting vulnerabilities in the US labor market that could hinder economic recovery.
- Bitcoin Plunge: Bitcoin (^BTCUSD) plummeted over 12% to a 1.25-year low, reflecting deepening negative momentum in the cryptocurrency market, with approximately $2 billion flowing out of Bitcoin ETFs in the past month, signaling a decline in investor confidence.
- Earnings Season Impact: Despite 150 S&P 500 companies set to report earnings this week, market focus on economic data intensifies, with S&P 500 earnings expected to grow by 8.4% in Q4, yet overall market sentiment remains suppressed by recent economic weakness.
See More
Bristol-Myers Squibb Q4 2025 Earnings Highlights
- Strong Growth Portfolio: Bristol-Myers Squibb's growth portfolio increased by 15% year-over-year in Q4 2025, reaching $7.4 billion and now accounting for nearly 60% of total revenue, demonstrating the company's execution strength and competitive position in its long-term growth strategy.
- Significant New Drug Contributions: Opdualag, Breyanzi, and Camzyos each contributed over $1 billion in annual sales, while Reblozyl exceeded $2 billion, indicating the company's success in drug development and market penetration.
- Optimistic Future Outlook: The company projects 2026 revenue between $46 billion and $47.5 billion, with adjusted EPS guidance of $6.05 to $6.35, reflecting ongoing confidence in the growth portfolio and the effectiveness of its cost-saving initiatives.
- Robust Financial Position: As of December 31, 2025, the company reported approximately $11 billion in cash and marketable securities, with $2 billion in operating cash flow for Q4 and the completion of a $10 billion debt paydown ahead of schedule, showcasing strong financial flexibility and ongoing investment capability.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
Tech Sector Rebound Fails to Offset Weekly Losses
- Nasdaq Rebound: The Nasdaq gained over 2% on Friday, yet still posted a 1.8% decline for the week, indicating ongoing investor concerns about tech stocks and the need to monitor future market trends.
- Dow Hits All-Time High: The Dow surged more than 1,200 points on Friday, closing at 50,115 with a weekly gain of 2.5%, reflecting a shift of funds from growth to value stocks, which may influence future investment strategies.
- Surge in Capital Expenditures: Alphabet announced that its capital expenditures for 2026 could exceed double the previous year, and despite a 0.5% drop in shares on Thursday, market confidence in its AI investments remains strong, signaling expectations for future growth.
- Software Stocks Crushed: Software stocks faced significant declines due to fears of AI encroaching on traditional SaaS companies, leading to pressure on the entire tech sector, prompting investors to remain vigilant about potential risks and opportunities within the industry.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Trump Administration Launches Drug Discount Website TrumpRx.gov
- Launch of Discount Platform: The Trump administration has unveiled TrumpRx.gov, a website designed to help consumers find discounts on brand-name drugs when paying cash, initially featuring 43 drugs from five companies, with more expected in the coming months.
- Significant Price Reductions: Monthly prices for Novo Nordisk's Ozempic and Wegovy will drop from $1,028 and $1,349 to an average of $350 and as low as $199, with Wegovy pills potentially falling to $149, significantly easing the financial burden on diabetes and obesity patients.
- Coupon Card Availability: The TrumpRx website lists coupon cards for some drugs that can be used at local pharmacies nationwide, although certain specialty medicines are excluded, reflecting the government's efforts to enhance drug accessibility for consumers.
- Future Expansion Plans: The White House indicated that discounts from 11 additional pharmaceutical companies that have agreements with the administration will be available soon, aiming to broaden drug options and improve health outcomes for Americans by lowering drug prices.
See More
US Stocks Plunge as Tech Sector Leads Decline
- Tech Sector Decline: Qualcomm's (QCOM) forecast of weaker-than-expected Q2 revenue led to an over 8% drop in its stock, triggering a sell-off across the tech sector, with the Nasdaq 100 index hitting a 2.5-month low, indicating waning investor confidence in technology stocks.
- Weak Labor Market Signals: Challenger's report revealed a staggering 117.8% year-over-year increase in job cuts for January, totaling 108,435, the highest for January since 2009, while initial jobless claims rose by 22,000 to 231,000, highlighting vulnerabilities in the US labor market that could hinder economic recovery.
- Bitcoin Plunge: Bitcoin (^BTCUSD) plummeted over 12% to a 1.25-year low, reflecting deepening negative momentum in the cryptocurrency market, with approximately $2 billion flowing out of Bitcoin ETFs in the past month, signaling a decline in investor confidence.
- Earnings Season Impact: Despite 150 S&P 500 companies set to report earnings this week, market focus on economic data intensifies, with S&P 500 earnings expected to grow by 8.4% in Q4, yet overall market sentiment remains suppressed by recent economic weakness.
See More
Bristol-Myers Squibb Q4 2025 Earnings Highlights
- Strong Growth Portfolio: Bristol-Myers Squibb's growth portfolio increased by 15% year-over-year in Q4 2025, reaching $7.4 billion and now accounting for nearly 60% of total revenue, demonstrating the company's execution strength and competitive position in its long-term growth strategy.
- Significant New Drug Contributions: Opdualag, Breyanzi, and Camzyos each contributed over $1 billion in annual sales, while Reblozyl exceeded $2 billion, indicating the company's success in drug development and market penetration.
- Optimistic Future Outlook: The company projects 2026 revenue between $46 billion and $47.5 billion, with adjusted EPS guidance of $6.05 to $6.35, reflecting ongoing confidence in the growth portfolio and the effectiveness of its cost-saving initiatives.
- Robust Financial Position: As of December 31, 2025, the company reported approximately $11 billion in cash and marketable securities, with $2 billion in operating cash flow for Q4 and the completion of a $10 billion debt paydown ahead of schedule, showcasing strong financial flexibility and ongoing investment capability.
See More
